What controls PTEN and what it controls (in prostate cancer) - PubMed (original) (raw)

What controls PTEN and what it controls (in prostate cancer)

Paramita M Ghosh. Asian J Androl. 2012 Jan.

No abstract available

PubMed Disclaimer

Figures

Figure 1

Figure 1

Schematic representation of the phosphatase and tensin homolog deleted on chromosome ten (PTEN)/Akt pathway and its relationship to the androgen receptor (AR) based on the results of three papers published recently by the laboratories of Charles Sawyers, Damu Tang and Hong Wu. mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol 3-kinase; PIP3, phosphatidyl inositol 3,4,5-trisphosphate; PIP2, phosphatidylinositol 4,5-bisphosphate.

References

    1. Attard G, de Bono JS. Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clin Cancer Res. 2011;17:3867–75. -PubMed
    1. Mulholland DJ, Dedhar S, Wu H, Nelson CC. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene. 2006;25:329–37. -PubMed
    1. Shen MM, Abate-Shen C. Pten inactivation and the emergence of androgen-independent prostate cancer. Cancer Res. 2007;67:6535–8. -PubMed
    1. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999;59:4291–6. -PubMed
    1. Bedolla R, Prihoda TJ, Kreisberg JI, Malik SN, Krishnegowda NK, et al. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res. 2007;13:3860–7. -PubMed

MeSH terms

Substances

LinkOut - more resources